Recent research highlights the effectiveness of Gal-3 inhibitors, such as inhaled GB0139 and orally administered ProLectin-M (PL-M), in modulating immune responses and reducing severe COVID-19 inflammation [9]. The gene discussed is LGALS3; the disease is COVID-19.